Literature DB >> 3940552

Sickle cell anemia patients have low erythropoietin levels for their degree of anemia.

J B Sherwood, E Goldwasser, R Chilcote, L D Carmichael, R L Nagel.   

Abstract

We have studied serum immunoreactive erythropoietin (SIE) levels in 28 patients with sickle cell anemia (SCA) without renal insufficiency and in 17 patients with nonhemoglobinopathy anemias of comparable severity using a sensitive radioimmunoassay procedure. An exponential relationship between SIE level and degree of anemia was noted in all patients. However, in nonhemoglobinopathy anemia, a sharp rise in the SIE level occurred as hemoglobin (Hb) levels fell below about 12 g/dL, whereas in sickle cell patients the increase was not marked until hemoglobin fell to about 9 g/dL. The response was more blunted in older SCA patients than in younger ones. A linear regression model relating SIE level to Hb level, presence/absence of SCA, and age explained 63% of the variation in SIE. We conclude that the serum erythropoietin levels in SCA increased at a lower hemoglobin concentration and are of a lower magnitude than that of the other anemias.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3940552

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Recombinant erythropoietin therapy in renal and nonrenal anemia.

Authors:  A J Erslev
Journal:  West J Med       Date:  1992-08

Review 2.  End stage renal disease in sickle cell disease: future directions.

Authors:  C R Tomson
Journal:  Postgrad Med J       Date:  1992-10       Impact factor: 2.401

3.  Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease.

Authors:  Caryn S Gonsalves; Chen Li; Marthe-Sandrine Eiymo Mwa Mpollo; Vinod Pullarkat; Punam Malik; Stanley M Tahara; Vijay K Kalra
Journal:  Biochem J       Date:  2015-04-16       Impact factor: 3.857

4.  High levels of neopterin and interleukin-3 in sickle cell disease patients.

Authors:  L Rodrigues; F F Costa; S T O Saad; H Z W Grotto
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 5.  Sickle cell states and the anaesthetist.

Authors:  D W Esseltine; M R Baxter; J C Bevan
Journal:  Can J Anaesth       Date:  1988-07       Impact factor: 5.063

6.  Steady state hemoglobin concentration and packed cell volume in homozygous sickle cell disease patients in Lagos, Nigeria.

Authors:  Akinsegun Akinbami; Adedoyin Dosunmu; Adewumi Adediran; Olajumoke Oshinaike; Adebola Phillip; Osunkalu Vincent; Arogundade Olanrewaju; Adelekan Oluwaseun
Journal:  Caspian J Intern Med       Date:  2012

7.  Serum immunoreactive erythropoietin of children in health and disease.

Authors:  K U Eckardt; W Hartmann; U Vetter; F Pohlandt; R Burghardt; A Kurtz
Journal:  Eur J Pediatr       Date:  1990-04       Impact factor: 3.183

Review 8.  Erythropoietin: a review.

Authors:  D M Ridley; F Dawkins; E Perlin
Journal:  J Natl Med Assoc       Date:  1994-02       Impact factor: 1.798

9.  Serum erythropoietin levels in thalassemia intermedia.

Authors:  F Dore; S Bonfigli; E Gaviano; S Pardini; P Cianciulli; G Papa; M Longinotti
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

10.  A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease.

Authors:  Abdullah Kutlar; Kenneth Ataga; Marvin Reid; Elliott P Vichinsky; Lynne Neumayr; Loray Blair-Britt; Richard Labotka; Jonathan Glass; Jeffrey R Keefer; William A Wargin; Ronald Berenson; Susan P Perrine
Journal:  Am J Hematol       Date:  2012-08-07       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.